Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation

NCT03468140 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Unable to recruit due to COVID 19

Conditions

End Stage Liver Disease

Interventions

DRUG: Eculizumab
OTHER: No intervention

Sponsor

Yale University

Collaborators

[object Object]
[object Object]